GlassScriptPhysician profile
Robert A Zimmerman
NPI 1669420931
$14,508.58
in general payments reported to CMS, 2019-2025
33 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 78% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $198 · 2021: $4,743 · 2022: $3,607 · 2023: $1,937 · 2024: $1,867 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,470 · Travel and Lodging: $2,098 · Gift: $37.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,469.90 |
| Travel and Lodging | $2,097.56 |
| Gift | $37.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,108.41 | 2021-2024 | Da Vinci Surgical System |
| Procept Biorobotics Corporation | $1,214.65 | 2022-2025 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $362.01 | 2019-2022 | |
| Coloplast Corp | $340.22 | 2022-2025 | Speedicath, Altis, Isiris Astent Removal Device |
| Medtronic, INC. | $311.79 | 2021-2025 | Interstim, Altaviva |
| Axonics, INC. | $252.46 | 2021-2024 | Axonics |
| Endo Pharmaceuticals INC. | $240.66 | 2020-2024 | Xiaflex, Aveed |
| Boston Scientific Corporation | $232.56 | 2019-2025 | General - Erectile Dysfunction, Rezum Generator |
| Sumitomo Pharma America, INC. | $229.53 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $137.29 | 2021-2022 | |
| Pfizer INC. | $134.30 | 2019-2025 | |
| Agiliti Health, INC. | $109.40 | 2024-2025 | Sonablate Hifu, Siemens Healthineers Varian Cryocare, Koelis Trinity Mri/US Fusion |
| Urogen Pharma, INC. | $104.77 | 2021-2025 | |
| Janssen Biotech, INC. | $94.98 | 2019-2025 | Erleada |
| Allergan, INC. | $93.20 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93.02 | 2019-2024 | Botox |
| Myriad Genetic Laboratories, INC. | $46.24 | 2022-2023 | Prolaris |
| Merck Sharp & Dohme LLC | $45.59 | 2021 | |
| Teleflex LLC | $38.87 | 2023-2025 | Urolift, Barrigel |
| Dexcom, INC. | $36.05 | 2021 | |
| Blue Earth Diagnostics | $35.97 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.26 | 2021 | |
| Medtronic USA, INC. | $27.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.25 | 2024 | |
| Olympus America INC. | $25.88 | 2025 | Itind System |
| Tolmar, INC. | $19.54 | 2025 | Eligard, Jatenzo |
| Kowa Pharmaceuticals America, INC. | $19.32 | 2023 | Seglentis |
| Ambu INC. | $17.16 | 2022 | |
| Rochester Medical Corporation | $16.95 | 2019 | |
| Lilly USA, LLC | $16.27 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $15.21 | 2020 | |
| Ethicon US, LLC | $14.99 | 2024 | Echelon; Endopath |
| Clarus Therapeutics INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.